Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?

Expert Review of Clinical Pharmacology

Volumn 5, Issue 1, 2012, Pages 43-54

  Handelsman, Yehuda ^a   Fonseca, Vivian ^b   Rosenstock, Julio ^c  

^a Metabolic Institute of America   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

combination therapy; high density lipoprotein cholesterol; low density lipoprotein cholesterol; triglycerides; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; COLESEVELAM; COLESTIPOL; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GOALS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPOPROTEINS, LDL; TREATMENT OUTCOME;

EID: 83055163336     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.73     Document Type: Review

References (90)

1. Krauss RM. Lipids and lipoproteins in patients with Type 2 diabetes. Diabetes Care 27(6), 1496-1504 (2004).
2. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
3. Di Angelantonio E, Sarwar N, Perry P et al.; The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993-2000 (2009).
4. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316(7134), 823-828 (1998).
5. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32(11), 1345-1361 (2011).
6. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123(20), 2292-2333 (2011).
7. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J. Clin. Endocrinol. Metab. 88(10), 4525-4532 (2003).
8. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27(Suppl. 1), S68-S71 (2004).
9. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am. J. Med. 122(5), 443-453 (2009).
10. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am. J. Cardiol. 98(10), 1405-1408 (2006).
11. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med. 259(3), 247-258 (2006).
12. Hoenig MR. Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc. Health Risk Manag. 4(1), 143-156 (2008).
13. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112(22), 3375-3383 (2005).
14. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am. J. Cardiol. 91(10), 1173-1177 (2003).
15. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294(3), 326-333 (2005).
16. Wagner AM, Perez A, Zapico E, Ordonez- Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of Type 2 diabetic patients. Diabetes Care 26(7), 2048-2051 (2003).
17. Howard BV, Best LG, Galloway JM et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29(2), 391-397 (2006).
18. Saely CH, Aczel S, Koch L et al. Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? Eur. J. Cardiovasc. Prev. Rehabil. 17(1), 94-99 (2010).
19. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet. Med. 26(2), 142-148 (2009).
20. Silva M, Matthews ML, Jarvis C et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 29(2), 253-260 (2007).
21. Crestor (rosuvastatin calcium) tablets, US prescribing information. AstraZeneca Pharmaceuticals LP, DE, USA (2011).
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (AdultTreatment Panel III). JAMA 285(19), 2486-2497 (2001).
23. Handelsman Y, Mechanick JI, Blonde L et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr. Pract. 17(Suppl. 2), 1-53 (2011).
24. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 34(Suppl. 1), S11-S61 (2011).
25. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
26. Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31(4), 811-822 (2008).
27. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685-696 (2004).
28. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005-2016 (2003).
29. Kearney PM, Blackwell L, Collins R et al.; Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117-125 (2008).
30. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol. 43(11), 2142-2146 (2004).
31. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29(6), 1220-1226 (2006).
32. Armitage J, Bowman L, Wallendszus K et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376(9753), 1658-1669 (2010).
33. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 25(7), 1198-1202 (2002).
34. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583-1592 (2001).
35. Vijayaraghavan K. Treatment of dyslipidemia in patients with Type 2 diabetes. Lipids Health Dis. 9(1), 144 (2010).
36. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension [MARINE] trial). Am. J. Cardiol. 108(5), 682-690 (2011).
37. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354(9177), 447-455 (1999).
38. Tavazzi L, Maggioni AP, Marchioli R et al.; GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645), 1223-1230 (2008).
39. Saito Y, Yokoyama M, Origasa H et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200(1), 135-140 (2008).
40. Sever PS, Poulter NR, Dahl et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with Type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 28(5), 1151-1157 (2005).
41. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with Type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29(7), 1478-1485 (2006).
42. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288(23), 2998-3007 (2002).
43. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353(3), 238-248 (2005).
44. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairshigh-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162(22), 2597-2604 (2002).
45. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370(9600), 1687-1697 (2007).
46. Rajamani K, Colman PG, Li LP et al. Effect of fenofibrate on amputation events in people with Type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373(9677), 1780-1788 (2009).
47. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357(9260), 905-910 (2001).
48. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. 95(2), 254-257 (2005).
49. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46(7), 1225-1228 (2005).
50. National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
51. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, Type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26(10), 1599-1607 (2004).
52. ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563-1574 (2010).
53. Chew EY, Ambrosius WT, Davis MD et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in Type 2 diabetes. N. Engl. J. Med. 363(3), 233-244 (2010).
54. McKenney JM, Jones PH, Bays HE et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192(2), 432-437 (2007).
55. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23), 3512-3517 (2004).
56. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22(11), 2243-2250 (2006).
57. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361(22), 2113-2122 (2009).
58. Brown BG, Brockenbrough A, Zhao X-Q et al. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation. 98(Suppl. I), I-635 (1998).
59. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. doi:10.1056/ NEJMoa1107579 (2011) (Epub ahead of print).
60. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am. Heart J. 161(3), 538-543 (2011).
61. Betteridge DJ. Lipid control in patients with diabetes mellitus. Nat. Rev. Cardiol. 8(5), 278-290 (2011).
62. Ballantyne CM. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. Am. J. Cardiol. 96(9A), 14K-19K (2005).
63. Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc. Diabetol. 9, 20 (2010).
64. Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated Type 2 diabetic patients. Diabetes Obes. Metab. 7(1), 88-97 (2005).
65. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes Vasc. Dis. Res. 3(2), 93-102 (2006).
66. Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr. Med. Res. Opin. 23(4), 713-719 (2007).
67. Blumenthal RS, Michos ED. The HALTS trial - halting atherosclerosis or halted too early? N. Engl. J. Med. 361(22), 2178-2180 (2009).
68. Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N. Engl. J. Med. 361(22), 2180-2183 (2009).
69. Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies inAtherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol. 55(24), 2721-2726 (2010).
70. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784), 2181-2192 (2011).
71. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South. Med. J. 99(3), 257-273 (2006).
72. Davidson MH, Toth P, Weiss S et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol. 24(6), 467-474 (2001).
73. Knapp HH, Schrott H, Ma P et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. 110(5), 352-360 (2001).
74. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158(2), 407-416 (2001).
75. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with Type 2 diabetes. Clin Ther. 29(1), 74-83 (2007).
76. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with Type 2 diabetes: a pooled analysis. Metabol. Syndr. Rel. Disord. 7(3), 255-258 (2009).
77. Goldfine AB, Fonseca VA, Abby SL, Jones MR. The use of colesevelam HCl with concomitant statin therapy in Type 2 diabetes mellitus improves glycemic control and the lipid profile. J. Clin. Lipidol. 2(3), 226 (2008).
78. El Harchaoui K, van der Steeg WA, Stroes ES et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 49(5), 547-553 (2007).
79. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106(15), 1930-1937 (2002).
80. Kuller L, Arnold A, Tracy R et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 22(7), 1175-1180 (2002).
81. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89-94 (2002).
82. Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113(12), 1556-1563 (2006).
83. Mora S, Szklo M, Otvos JD et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192(1), 211-217 (2007).
84. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 213(1), 1-7 (2010).
85. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with Type 2 diabetes. Atherosclerosis 204(2), 342-344 (2009).
86. Rosenstock J, Fonseca VA, Garvey WT et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early Type 2 diabetes. Endocr. Pract. 16(4), 629-640 (2010).
87. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351-364 (1984).
88. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353(9153), 617-622 (1999).
89. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358(6), 580-591 (2008).
90. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348(5), 383-393 (2003).